# Royalty Pharma (RPRX): value investors who own it

2 value investors held Royalty Pharma in their Q3 2026 13F, led by Dorsey Asset Management, Horizon Kinetics.

## 13F holders

| Manager | Portfolio | Value | Change | Quarters held |
| --- | --- | --- | --- | --- |
| Dorsey Asset Management | 8.8% | $138m | Added +7.9% | 4 |
| Horizon Kinetics | 0.2% | $19.3m | Added +1.2% | 22 |

## Directors buying and selling (Form 4, last 12 months)

| Date | Who | Role | Bought or sold | Shares | Value |
| --- | --- | --- | --- | --- | --- |
| 2026-10-05 | Urist Marshall | EVP, Research & Investments | Sold | 4126 | $236k |
| 2026-09-28 | Urist Marshall | EVP, Research & Investments | Sold | 4126 | $239k |
| 2026-09-22 | Hite Christopher | EVP & Chairman, Partnering | Sold | 96073 | $5.6m |
| 2026-09-22 | Hite Christopher | EVP & Chairman, Partnering | Sold | 3927 | $231k |
| 2026-08-18 | Hite Christopher | EVP & Chairman, Partnering | Sold | 100000 | $6.0m |
| 2026-08-13 | Coyne Terrance P. | EVP & CFO | Sold | 9230 | $541k |
| 2026-08-13 | Coyne Terrance P. | EVP & CFO | Sold | 1772 | $105k |

## Fund holders

| Fund | Manager | Weight | Value | As at |
| --- | --- | --- | --- | --- |
| Horizon Kinetics Inflation Beneficiaries ETF | Horizon Kinetics | 1.2% | $18.3m | 2026-06-30 |

Source: SEC filings, via moatshark (https://www.moatshark.com/s/rprx). Values traded and returns are estimates. Not investment advice. Built 2026-10-21.